Brahm Nancy C, McElwain David L, Brown Robert C
Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma (UO), Tulsa 74135-2512, USA.
Am J Health Syst Pharm. 2007 Apr 15;64(8):827-9. doi: 10.2146/ajhp060209.
A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented.
The patient was a 40-year-old male with developmental disabilities. He was nonverbal, profoundly mentally retarded, and diagnosed with obsessive compulsive disorder (OCD) and orthopedic problems. He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage. The patient was antipsychotic naive before initiation of aripiprazole 5 mg daily. Concurrent medications at the time of EPS onset included oxazepam, baclofen, and citalopram. Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures. Aripiprazole, 5 mg daily, was initiated in November 2004 as an augmentation strategy for the diagnosis of OCD. Facial, tongue, and arm movements were first reported approximately five weeks after the initiation of aripiprazole. Initial symptoms resolved after approximately 24 hours. The dosage was increased to 10 mg daily two weeks later. Dystonic episodes continued on an intermittent basis, and the patient presented with lower-lip thrusting and upper-limb athetosis. These movements interfered with the patient's eating, chewing, and holding of utensils. Several of the standard treatment strategies for EPS were used. Initially, diphenhydramine hydrochloride 25 mg was administered orally every six hours. The patient's movements resolved following diphenhydramine administration. Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder.
A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole.
本文报告一例从未接受过抗精神病药物治疗且无运动障碍病史的发育障碍男性在服用阿立哌唑后出现锥体外系症状(EPS)的病例。
该患者为一名40岁的发育障碍男性。他无法言语,智力严重低下,被诊断患有强迫症(OCD)和骨科问题。他出现了间歇性运动,可能与使用阿立哌唑继发的EPS相符。在开始每日服用5毫克阿立哌唑之前,该患者未曾使用过抗精神病药物。EPS发作时的同时服用药物包括奥沙西泮、巴氯芬和西酞普兰。巴氯芬和奥沙西泮是因右侧偏瘫挛缩而开具的。2004年11月开始每日服用5毫克阿立哌唑,作为强迫症诊断的强化治疗策略。在开始服用阿立哌唑约五周后首次报告面部、舌头和手臂运动。最初的症状在约24小时后缓解。两周后剂量增加至每日10毫克。肌张力障碍发作持续间歇性出现,患者出现下唇前突和上肢手足徐动症。这些运动干扰了患者的进食、咀嚼和握持餐具。使用了几种EPS的标准治疗策略。最初,每六小时口服25毫克盐酸苯海拉明。服用苯海拉明后患者的运动症状缓解。随后因阿立哌唑对OCD缺乏疗效且出现运动障碍而停药。
一名无运动障碍病史的发育障碍患者在开始服用阿立哌唑后出现了EPS。